CL2012000591A1 - Compuestos derivados de pirimidina o 1,3,5-triazina, antagonistas de hepcidina; composicion farmaceutica; combinacion farmaceutica util en el tratamiento de desordenes del metabolismo del hierro y los sintomas asociados. - Google Patents

Compuestos derivados de pirimidina o 1,3,5-triazina, antagonistas de hepcidina; composicion farmaceutica; combinacion farmaceutica util en el tratamiento de desordenes del metabolismo del hierro y los sintomas asociados.

Info

Publication number
CL2012000591A1
CL2012000591A1 CL2012000591A CL2012000591A CL2012000591A1 CL 2012000591 A1 CL2012000591 A1 CL 2012000591A1 CL 2012000591 A CL2012000591 A CL 2012000591A CL 2012000591 A CL2012000591 A CL 2012000591A CL 2012000591 A1 CL2012000591 A1 CL 2012000591A1
Authority
CL
Chile
Prior art keywords
triazine
pyrimidine
treatment
compounds derived
pharmaceutical composition
Prior art date
Application number
CL2012000591A
Other languages
English (en)
Inventor
Wilm Buhr
Franz Durrenberger
Susanna Burckhardt
Peter Otto Geisser
Felix Funk
Julia Marie Bainbridge
Vincen Corden
Original Assignee
Vifor Int Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41490366&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012000591(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vifor Int Ag filed Critical Vifor Int Ag
Publication of CL2012000591A1 publication Critical patent/CL2012000591A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
    • C07D251/18—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/54—Three nitrogen atoms
    • C07D251/66—Derivatives of melamine in which a hetero atom is directly attached to a nitrogen atom of melamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nutrition Science (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Compuestos derivados de triazina y pirimidina, antagonistas de hepcidina; composición farmacéutica; combinación farmacéutica útil en el tratamiento de desórdenes del metabolismo del hierro y los síntomas asociados.
CL2012000591A 2009-09-02 2012-03-02 Compuestos derivados de pirimidina o 1,3,5-triazina, antagonistas de hepcidina; composicion farmaceutica; combinacion farmaceutica util en el tratamiento de desordenes del metabolismo del hierro y los sintomas asociados. CL2012000591A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09169286 2009-09-02

Publications (1)

Publication Number Publication Date
CL2012000591A1 true CL2012000591A1 (es) 2012-08-03

Family

ID=41490366

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012000591A CL2012000591A1 (es) 2009-09-02 2012-03-02 Compuestos derivados de pirimidina o 1,3,5-triazina, antagonistas de hepcidina; composicion farmaceutica; combinacion farmaceutica util en el tratamiento de desordenes del metabolismo del hierro y los sintomas asociados.

Country Status (21)

Country Link
US (1) US20120202806A1 (es)
EP (1) EP2473486B2 (es)
JP (1) JP2013503833A (es)
KR (1) KR20120061055A (es)
CN (1) CN102482232A (es)
AR (1) AR077999A1 (es)
AU (1) AU2010291318A1 (es)
BR (1) BR112012008109A2 (es)
CA (1) CA2769553A1 (es)
CL (1) CL2012000591A1 (es)
CR (1) CR20120097A (es)
DO (1) DOP2012000057A (es)
EA (1) EA201200402A1 (es)
ES (1) ES2554855T3 (es)
IL (1) IL218253A0 (es)
MA (1) MA33538B1 (es)
MX (1) MX2012002626A (es)
SG (1) SG178984A1 (es)
TN (1) TN2012000045A1 (es)
TW (1) TW201113272A (es)
WO (1) WO2011026835A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR077999A1 (es) 2009-09-02 2011-10-05 Vifor Int Ag Antagonistas de pirimidin y triazin-hepcidina
DE102010002558A1 (de) * 2009-11-20 2011-06-01 Symrise Ag Verwendung physiologischer Kühlwirkstoffe und Mittel enthaltend solche Wirkstoffe
CN103052628B (zh) 2010-07-20 2016-05-18 韦斯塔隆公司 三嗪类和嘧啶类杀虫剂
CZ305457B6 (cs) * 2011-02-28 2015-09-30 Ústav organické chemie a biochemie, Akademie věd ČR v. v. i. Pyrimidinové sloučeniny inhibující tvorbu oxidu dusnatého a prostaglandinu E2, způsob výroby a použití
MX342326B (es) 2011-09-27 2016-09-26 Novartis Ag 3-pirimidin-4-il-oxazolidin-2-onas como inhibidoras de idh mutante.
JP2014237590A (ja) * 2011-09-30 2014-12-18 アステラス製薬株式会社 ２−（ピリジン−２−イル）ピリミジン−４−アミン化合物又はその塩
UY34632A (es) 2012-02-24 2013-05-31 Novartis Ag Compuestos de oxazolidin- 2- ona y usos de los mismos
BR112014026703B1 (pt) 2012-04-24 2022-10-25 Vertex Pharmaceuticals Incorporated Inibidores de dna-pk e seus usos, composição farmacêutica e seus usos, e método de sensibilização de uma célula
US9296733B2 (en) 2012-11-12 2016-03-29 Novartis Ag Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
AU2013370417A1 (en) * 2012-12-28 2015-07-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibitors of the USP1/UAF1 deubiquitinase complex and uses thereof
JP6120311B2 (ja) * 2013-02-12 2017-04-26 学校法人銀杏学園 ポリフェノール化合物
RS62649B1 (sr) 2013-03-12 2021-12-31 Vertex Pharma Inhibitori dnk-pk
BR112015023412A8 (pt) 2013-03-14 2018-01-23 Novartis Ag 3-pirimidin-4-il-oxazolidin-2-onas como inibidores de idh mutante, sua composição farmacêutica e seu uso.
UY35735A (es) 2013-09-16 2015-04-30 Bayer Pharma AG Trifluorometilpirimidinonas disustituidas y su uso
EP3424920B1 (en) 2013-10-17 2020-04-15 Vertex Pharmaceuticals Incorporated Co-crystals of (s)-n-methyl-8-(1-((2'-methyl-[4,5'-bipyrimidin]-6-yl)amino)propan-2-yl)quinoline-4-carboxamide and deuterated derivatives thereof as dna-pk inhibitors
WO2017190050A1 (en) 2016-04-28 2017-11-02 Cornell University Inhibitors of soluble adenylyl cyclase
AU2017275657B2 (en) 2016-06-02 2021-08-19 Novartis Ag Potassium channel modulators
JP2019529475A (ja) 2016-09-27 2019-10-17 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ｄｎａ損傷剤とｄｎａ−ｐｋ阻害剤との組合せ物を使用する、がんを処置するための方法
BR112019014814B1 (pt) 2017-01-23 2024-03-12 Novartis Ag Compostos, composições farmacêuticas dos mesmos e seus usos no tratamento de doenças associadas à disfunção de canais iônicos de potássio
US10172856B2 (en) 2017-04-06 2019-01-08 Janssen Pharmaceutica Nv 2,4-diaminopyrimidine derivatives as histamine H4 modulators
ES2967435T3 (es) 2017-08-31 2024-04-30 Basf Se Uso de principios activos refrescantes fisiológicos y productos que contienen dichos principios activos
CA3181577A1 (en) * 2020-04-28 2021-11-04 Global Blood Therapeutics, Inc. Thieno pyrimidines as ferroportin inhibitors
EP4142732A1 (en) * 2020-04-28 2023-03-08 Global Blood Therapeutics, Inc. Methods of use for pyrimidines as ferroportin inhibitors
EP4143178A1 (en) 2020-04-28 2023-03-08 Global Blood Therapeutics, Inc. Cycloalkyl pyrimidines as ferroportin inhibitors
CN112028838B (zh) * 2020-08-04 2022-07-01 精华制药集团南通有限公司 一种2-乙氧基-5-氟尿嘧啶杂质的制备方法
CN113683596B (zh) * 2021-08-17 2023-02-10 上海应用技术大学 一种嘧啶类端锚聚合酶2抑制剂及其制备方法和应用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2131004A1 (en) * 1992-02-28 1993-09-02 Hideshi Kobayashi S-triazine derivative and remedy for estrogen-dependent disease containing said derivative as effective component
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
US7166448B1 (en) 1999-05-10 2007-01-23 Children's Medical Center Corproation Ferroportin1 nucleic acids and proteins
AU2002321105A1 (en) 2001-05-25 2002-12-16 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of hepcidin for preparing a medicament for treating disorders of iron homeostasis
HUP0402352A2 (hu) 2001-06-19 2005-02-28 Bristol-Myers Squibb Co. Foszfodiészteráz (PDE) 7 inhibitorként alkalmazható pirimidinszármazékok és ezeket tartalmazó gyógyszerkészítmények
AU2002361033B8 (en) * 2002-01-02 2009-01-29 Actelion Pharmaceuticals Ltd. Novel alkansulfonamides as endothelin antagonists
TW200407315A (en) 2002-04-23 2004-05-16 Sankyo Co Pyrimidine derivatives
GB0226724D0 (en) 2002-11-15 2002-12-24 Merck Sharp & Dohme Therapeutic agents
RU2359268C2 (ru) 2002-11-19 2009-06-20 ДиАрДжи ИНТЕРНЭШНЛ, ИНК. Способ диагностики заболеваний путем скрининга тканей, крови или жидкостей организма животных или человека на предмет обнаружения нефизиологических уровней гепсидина и его терапевтическое применение
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
US8614204B2 (en) 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
ATE485824T1 (de) 2004-04-13 2010-11-15 Icagen Inc Polycyclische pyrimidine als kaliumionenkanal- modulatoren
US7723063B2 (en) 2004-04-28 2010-05-25 Intrinsic Lifesciences Methods for measuring levels of bioactive human hepcidin
EP1791818A1 (en) * 2004-09-14 2007-06-06 The Genetics Company, Inc. Hydrazone derivatives and their use as beta secretase inhibitors
US20060161001A1 (en) 2004-12-20 2006-07-20 Amgen Inc. Substituted heterocyclic compounds and methods of use
GB0503962D0 (en) * 2005-02-25 2005-04-06 Kudos Pharm Ltd Compounds
US9771331B2 (en) * 2005-04-22 2017-09-26 The Johns Hopkins University Methods of identifying neuroprotective compounds for retinal ganglion cells
US20060293343A1 (en) 2005-05-18 2006-12-28 Asahi Kasei Pharma Corporation Pyrimidine derivatives
US7534764B2 (en) 2005-06-29 2009-05-19 The Regents Of The University Of California Competitive regulation of hepcidin mRNA by soluble and cell-associated hemojuvelin
CA2654670A1 (en) 2006-07-06 2008-01-10 Boehringer Ingelheim International Gmbh New compounds
EP2066687A4 (en) 2006-09-21 2010-12-08 Alnylam Pharmaceuticals Inc COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF HAMP GENE
ES2535212T3 (es) 2006-10-04 2015-05-06 Janssen Sciences Ireland Uc Carboxamido-4-[(4-piridil)amino]-pirimidinas para el tratamiento de la hepatitis C
WO2008088727A2 (en) * 2007-01-12 2008-07-24 Concert Pharmaceuticals, Inc. Endothelin receptor antagonists
WO2008097461A2 (en) 2007-02-02 2008-08-14 Amgen Inc Hepcidin and hepcidin antibodies
CL2008000467A1 (es) 2007-02-14 2008-08-22 Janssen Pharmaceutica Nv Compuestos derivados de 2-aminopirimidina, moduladores del receptor histamina h4; su procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar un trastorno inflamatorio seleccionado de alegia, asma
DE102007010801A1 (de) 2007-03-02 2008-09-04 Bayer Cropscience Ag Diaminopyrimidine als Fungizide
CL2008000666A1 (es) 2007-03-07 2008-06-13 Xenon Pharmaceuticals Inc Compuestos derivados de triciclos sustituidos, inhibidores del transportador de metales divalentes-1; y uso para tratar una enfermedad asociada con un trastorno del hierro.
AR065785A1 (es) 2007-03-19 2009-07-01 Xenon Pharmaceuticals Inc Compuestos biarilo y biheteroarilo de utilidad en el tratamiento de trastornos de hierro
US7705018B2 (en) 2007-03-23 2010-04-27 Amgen Inc. Substituted quinolines and their uses in treatment of inflammatory and related conditions
WO2008121861A2 (en) 2007-03-28 2008-10-09 Xenon Pharmaceuticals Inc. Pyrazole and pyrrole compounds useful in treating iron disorders
JP2010208945A (ja) 2007-06-01 2010-09-24 Mitsubishi Tanabe Pharma Corp 複素環化合物
WO2008151288A2 (en) 2007-06-05 2008-12-11 Xenon Pharmaceuticals Inc. Aromatic and heteroaromatic compounds useful in treating iron disorders
JP5586460B2 (ja) 2007-07-17 2014-09-10 ライジェル ファーマシューティカルズ， インコーポレイテッド Ｐｋｃ阻害剤としての環状アミン置換ピリミジンジアミン
GR1006896B (el) 2007-08-24 2010-07-20 Ελληνικο Ινστιτουτο Παστερ, Μεθοδος παραγωγης μιας πεπτιδικης ορμονης
EP2181098B1 (en) 2007-08-30 2011-03-02 Dow AgroSciences LLC 2-(substituted phenyl)-6-amino-5-alkoxy, thioalkoxy and aminoalkyl-4-pyrimidinecarboxylates and their use as herbicides
CA2701694A1 (en) 2007-10-02 2009-04-09 Sophie Vaulont Antigen-binding proteins having specificity for human hepcidin
JO2828B1 (en) 2007-11-02 2014-09-15 ايلي ليلي اند كومباني Anti-Hepsidine antibodies and their uses
US20110124649A1 (en) * 2007-11-09 2011-05-26 The Johns Hopkins University Inhibitors of human methionine aminopeptidase 1 and methods of treating disorders
KR20100108390A (ko) * 2007-12-19 2010-10-06 버텍스 파마슈티칼스 인코포레이티드 ＪＡＫ２ 억제제로서 유용한 피라졸로［１，５－ａ］피리미딘
WO2009093981A1 (en) * 2008-01-23 2009-07-30 S Bio Pte Ltd Triazine compounds as kinase inhibitors
RU2434634C1 (ru) 2008-02-08 2011-11-27 Шисейдо Компани Лтд. Отбеливающий агент и композиция для кожи для наружного применения
ES2524883T3 (es) * 2008-03-18 2014-12-15 Merck Sharp & Dohme Corp. 4-Hidroxipirimidina-5-carboxamidas sustituidas
AR077999A1 (es) 2009-09-02 2011-10-05 Vifor Int Ag Antagonistas de pirimidin y triazin-hepcidina

Also Published As

Publication number Publication date
EP2473486B1 (de) 2015-10-28
JP2013503833A (ja) 2013-02-04
MA33538B1 (fr) 2012-08-01
CN102482232A (zh) 2012-05-30
MX2012002626A (es) 2012-04-20
AR077999A1 (es) 2011-10-05
IL218253A0 (en) 2012-04-30
KR20120061055A (ko) 2012-06-12
EP2473486A1 (de) 2012-07-11
WO2011026835A1 (de) 2011-03-10
EP2473486B2 (de) 2021-09-22
TW201113272A (en) 2011-04-16
CA2769553A1 (en) 2011-03-10
TN2012000045A1 (en) 2013-09-19
ES2554855T3 (es) 2015-12-23
DOP2012000057A (es) 2012-08-31
AU2010291318A1 (en) 2012-03-01
US20120202806A1 (en) 2012-08-09
CR20120097A (es) 2012-09-03
SG178984A1 (en) 2012-04-27
BR112012008109A2 (pt) 2019-09-24
EA201200402A1 (ru) 2012-08-30

Similar Documents

Publication Publication Date Title
CL2012000591A1 (es) Compuestos derivados de pirimidina o 1,3,5-triazina, antagonistas de hepcidina; composicion farmaceutica; combinacion farmaceutica util en el tratamiento de desordenes del metabolismo del hierro y los sintomas asociados.
CL2009000873A1 (es) Compuestos derivados de ciclohepta[b]piridina, antagonistas del receptor de cgrp; composicion farmaceutica; y uso para el tratamiento de la migrana.b
CL2006003736A1 (es) Compuestos derivados de triazina o pirimidina sustituida, antagonistas del receptor de prokineticina 1, composicion farmaceutica; y uso en el tratamiento de trastornos gastrointestinales.
CL2012002250A1 (es) Compuestos heterociclicos fusionados derivados de pirimidinonas, inhibidores potentes de cdc7; composicion farmaceutica; y su uso en la prevencion o el tratamiento del cancer.
ATE469895T1 (de) Cgrp-rezeptorantagonisten
CL2008002097A1 (es) Compuestos derivados de heterociclos condensados sustituidos, inhibidores de cinasa de fosfatidil-inositol-3; composicion farmaceutica; y uso en el tratamiento del cancer.
UY31619A1 (es) Compuestos espiro como antagonistas del receptor npy y5
EA201001030A1 (ru) Конденсированные соединения пиридина, пиримидина и триазина в качестве ингибиторов клеточного цикла
CL2011002942A1 (es) Compuestos derivados de 2,4-diamino-pirimidina, agonistas de receptor tipo toll-7 (tlr7); composicion farmaceutica; y su uso para el tratamiento del cancer.
SV2009003417A (es) Antagonistas piridil piperidina del receptor de orexina
ECSP11011541A (es) Antagonistas de la trayectoria hedgehog de ftalazina disustituida
CR10309A (es) "compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1"
CL2008001705A1 (es) Compuestos derivados de heterociclos de nitrogeno; y uso del compuesto para el tratamiento de enfermedades o trastornos relacionados con el receptor de histamina h3.
ECSP077421A (es) Compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1
CL2008003159A1 (es) Compuestos derivados de diaminas sustituidas, sus sales farmaceuticamente aceptables o sus solvatos; compuestos intermediarios; utiles como agentes antiobesidad, mediados por la inhibicion del receptor npy y5.
EA201071248A1 (ru) Дизамещенные фталазиновые антагонисты пути hedgehog
MX2009010960A (es) Compuestos heterociclicos y sus metodos de uso.
CL2007002757A1 (es) Compuestos derivados de 1,2,4-triazina sustituida; composicion farmaceutica; y uso en el tratamiento o prevencion del reflujo gastroesofagico y ansiedad.
CL2011002467A1 (es) Compuestos derivados de 6-(3-aza-biciclo[3.1.0]hex-3-il)-2-fenilpirimidinas, antagonistas del receptor p2y 12; composicion farmaceutica que los comprende; y su uso en el tratamiento de trastornos oclusivos. pct fase nacional.
ECSP11011021A (es) Antagonistas de la via hedgehog de ftalazina disustituida
MX2018011622A (es) Pirimidinas y sus variantes, y usos de las mismas.
CL2009000119A1 (es) Compuestos derivados de amino-bencimidazoles sustituidos; composicion farmaceutica; y su uso en el tratamiento del alzheimer.
CL2008003266A1 (es) Compuestos derivados de pirimidindiona y triazindiona sustituidas con cicloguanidina, utiles como antagonista del receptor de procineticina; composicion farmaceutica que comprende dichos compuestos; y uso en el tratamiento de enfermedades gastrointestinales.
IL206359A0 (en) Sulfonamides as orexin antagonists
EA201201623A1 (ru) Лечение диабета 2 типа